**Anal Carcinoma Treatment Regimens**

**Clinical Trials:** The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment.

Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies.

These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

---

### Localized Cancer

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| Fluorouracil + Mitomycin + Radiotherapy (XRT)<sup>3,4,10</sup> [preferred] | **Days 1-4: 29-32:** Fluorouracil 1,000mg/m² IV continuous infusion over 24 hours  
**Days 1 and 29:** Mitomycin 10mg/m² (max 20mg) IV push, with Concurrent XRT  
**OR**  
**Days 1-4: 29-32:** Fluorouracil 1,000mg/m² IV continuous infusion over 24 hours  
**Day 1:** Mitomycin 12mg/m² (max 20mg) IV push, with Concurrent XRT. |

| Capecitabine + Mitomycin + XRT<sup>3,6-8</sup> [preferred] | **Days 1-5: 8-12: 15-19: 22-26: 29-33: 36-38:** Capecitabine 825mg/m² orally twice daily  
**Days 1 and 29:** Mitomycin 10mg/m² IV (max 20 mg) push, with Concurrent XRT  
**OR**  
**Days 1-5: 8-12: 15-19: 22-26: 29-33: 36-38:** Capecitabine 825 mg/m² orally twice daily  
**Day 1:** Mitomycin 12mg/m² (max 20mg) IV push, with Concurrent XRT. |

| Fluorouracil + Cisplatin + XRT<sup>2,4,9,10</sup> (Category 2B) | **Days 1-4: 29-32:** Fluorouracil 1,000mg/m² IV continuous infusion over 24 hours  
**Days 1 and 29:** Cisplatin 75mg/m² IV over 60 minutes  
Administer for one 56-day cycle without XRT, then one 56-day cycle with XRT. |

### Metastatic Cancer

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| Fluorouracil + Cisplatin<sup>2,9,11,12</sup> | **Day 1:** Cisplatin 60mg/m² IV over 60 minutes  
**Days 1-4:** Fluorouracil 1,000mg/m² IV continuous infusion over 24 hours daily  
Repeat cycle every 3 weeks  
**OR**  
**Day 1:** Cisplatin 75mg/m² IV over 60 minutes  
**Days 1-5:** Fluorouracil 750mg/m² IV continuous infusion over 24 hours daily  
Repeat cycle every 4 weeks. |

| mFOLFOX<sup>6,13-15</sup> | **Day 1:** Oxaliplatin 85mg/m² IV over 2 hours, with:  
**Day 1:** Leucovorin 400mg/m² IV over 2 hours, followed by:  
**Day 1:** Fluorouracil 400mg/m² IV push, followed by:  
**Days 1-2:** Fluorouracil 1,200 mg/m² IV continuous infusion daily (2,400 mg/m² IV over 46-48 hours)  
Repeat cycle every 2 weeks. |

| Carboplatin + Paclitaxel<sup>11,16-18</sup> [preferred] | **Day 1:** Paclitaxel 175mg/m² over 3 hours, followed by:  
**Day 1:** Carboplatin AUC 5 IV over 30 minutes  
Repeat cycle every 3 weeks. |

| FOLCIS (Fluorouracil Continuous Infusion/Leucovorin/Cisplatin)<sup>2,5,14,19</sup> | **Day 1:** Cisplatin 40mg/m² IV over 30 minutes, with:  
**Day 1:** Leucovorin 400mg/m² IV over 30 minutes, followed by:  
**Day 1:** Fluorouracil 400mg/m² IV push, followed by:  
**Days 1-2:** Fluorouracil 1000mg/m² IV continuous infusion daily (2,000mg/m² IV over 46-48 hours)  
Repeat cycle every 2 weeks. |

---

1 CancerTherapyAdvisor.com
## Subsequent Therapy

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOsing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nivolumab</strong></td>
<td>Day 1: Nivolumab 240mg IV over 30 minutes Repeat cycle every 2 weeks.</td>
</tr>
<tr>
<td><strong>[preferred]</strong></td>
<td>OR Day 1: Nivolumab 3mg/m² IV over 30 minutes Repeat cycle every 2 weeks.</td>
</tr>
<tr>
<td><strong>[preferred]</strong></td>
<td>OR Day 1: Nivolumab 480mg IV over 30 minutes Repeat cycle every 4 weeks.</td>
</tr>
<tr>
<td><strong>Pembrolizumab</strong></td>
<td>Day 1: Pembrolizumab 200mg IV over 30 minutes Repeat cycle every 3 weeks.</td>
</tr>
<tr>
<td><strong>[preferred]</strong></td>
<td>OR Day 1: Pembrolizumab 2mg/m² IV over 30 minutes Repeat cycle every 3 weeks.</td>
</tr>
</tbody>
</table>

**Note:** Modification to cancer treatment should not be made solely on the basis of HIV status.

### References

2. 5-Fluorouracil (Fluorouracil injection) [package insert]. Irvine, CA: Spectrum Pharmaceuticals; 2016.